HC Wainwright Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $16.00

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) had its price target hoisted by investment analysts at HC Wainwright from $15.00 to $16.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright also issued estimates for Larimar Therapeutics’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 […]

Leave a Reply

Your email address will not be published.

Previous post Dragonfly Energy (NASDAQ:DFLI) Lowered to Neutral Rating by Alliance Global Partners
Next post HC Wainwright Lowers Neurogene (NASDAQ:NGNE) Price Target to $50.00